Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

A9730

Sigma-Aldrich

Adefovir dipivoxil

Sinonimo/i:

9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C20H32N5O8P
Numero CAS:
142340-99-6
Peso molecolare:
501.47
Numero MDL:
MFCD00869897
Codice UNSPSC:
51102829
ID PubChem:
329771057
NACRES:
NA.76
Prezzi e disponibilità al momento non sono disponibili

Origine biologica

synthetic

Saggio

≥98% (HPLC)

Stato

solid

Solubilità

ethanol: 50 mg/mL

Spettro attività antibiotica

viruses

Modalità d’azione

enzyme | inhibits

Temperatura di conservazione

−20°C

Stringa SMILE

CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C

InChI

1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)
WOZSCQDILHKSGG-UHFFFAOYSA-N

Azioni biochim/fisiol

Adefovir is an antiviral acyclic nucleoside phosphonate (ANP) analog that works by blocking reverse transcriptase.[1] It is an inhibitor of duck hepatitis B virus (DHBV) replication that inhibits covalently closed circular DNA (CCC DNA) amplification.[2] Cytotxicity is induced by Human Renal Organic Anion Transporter 1 (hOAT1).[3] Adefovir is an Inhibitor of edema factor (EF)-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages [4].

Altre note

Keep container tightly closed in a dry and well-ventilated place.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302 + H312 + H332

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
BCCL6998
BCCJ4542
BCCD7131
BCBV6452
BCBT6322

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Patrick Marcellin et al.
The New England journal of medicine, 348(9), 808-816 (2003-02-28)
In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains. We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10
Man-Fung Yuen et al.
Expert opinion on pharmacotherapy, 5(11), 2361-2367 (2004-10-27)
Adefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and
Myron J Tong et al.
Seminars in liver disease, 24 Suppl 1, 37-44 (2004-06-12)
Adefovir dipivoxil, a nucleotide analog of adenosine monophosphate, is an antiviral agent that suppresses hepatitis B virus (HBV) replication through inhibition of DNA polymerase and by chain termination. To determine the effectiveness of adefovir, three populations of patients with chronic
J Jones et al.
Health technology assessment (Winchester, England), 13(35), 1-172 (2009-07-18)
To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-alpha) for the treatment of chronic hepatitis B (CHB). Thirteen bibliographic databases were searched including MEDLINE, EMBASE and the
Xiaokun Shen et al.
Scientific reports, 6, 38778-38778 (2016-12-13)
A pressing need exists for improved therapeutic options for chronic hepatitis B (CHB). Pegylated-interferon-alpha (Peg-IFN-α) achieves sustained off-treatment responses in many cases because of its direct anti-viral effects and regulation of the immune response. However, non-responsiveness to Peg-IFN-α is frequent
Visualizza tutti i documenti correlati

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.